Drug Search Results
More Filters [+]

Selurampanel

Alternative Names: selurampanel, bgg-492, bgg492, bgg 492, BGG492A
Latest Update: 2022-12-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: KAR Antagonist,AMPA Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Selurampanel

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Tinnitus|Epilepsy, Reflex|Seizures|Muscle Spasticity|Migraine Disorders|Multiple Sclerosis|Epilepsy|Migraine with Aura|Migraine without Aura|Adrenocortical Adenoma|Sarcoma, Endometrial Stromal|Adenoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-7041-83/hah

N/A

Not yet recruiting

Depressive Disorder

2021-05-28

CBGG492A2215

P2

Withdrawn

Multiple Sclerosis|Muscle Spasticity

2018-03-01

CBGG492A2214

P2

Withdrawn

Migraine Disorders

2016-11-01

2013-003431-29

P2

Completed

Adenoma

2015-09-21

Recent News Events